Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Vanguard Total World Stock Index Fund ETF — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B), while Vanguard Total World Stock Index Fund ETF trades at $159.91 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| TAK | VT | |
|---|---|---|
Market Cap | $58.74B | $101.70B |
Volume | 3,110,994 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $19.05 | $162.39 |
52-Week Low | $13.23 | $134.19 |
Typical Hold Time | 1 Days | 53 Days |
Enterprise Value | $86.65B | — |
Dividend Yield | 3.33% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vanguard Total World Stock ETF (VT) trades at $159.84, up 0.13% with a bearish technical signal from moving averages. The ETF provides exposure to over 9,700 global stocks with a 0.06% expense ratio, though key financial ratios remain unavailable. Recent news highlights VT's diversification benefits and competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF.
VT offers broad global diversification but faces headwinds from technical bearish signals and expense ratio competition. The outlook remains neutral with institutional interest mixed; risks include market volatility and geopolitical factors. Long-term investors may value its comprehensive market coverage despite near-term technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →